The regenerative effects of PDRN have been most thoroughly examined in skin repair. Both preclinical and clinical research demonstrate that PDRN promotes blood vessel growth, modulates cytokine levels, and accelerates tissue healing. This leads to better healing outcomes in chronic diabetic foot ulcers, pressure ulcers, venous leg ulcers, and also facilitates quicker epithelial regeneration in surgical donor sites and corneal wounds [1][2][8].
Polydeoxyribonucleotide (PDRN) is a unique regenerative agent derived from purified DNA polymers. It was first extracted from salmon sperm, such as Oncorhynchus mykiss and Oncorhynchus keta. PDRN is composed of deoxyribonucleotide fragments with molecular weights between 50 and 1,500 kDa.
PDRN was first approved in Italy in 1994 for the treatment of superficial wounds and skin ulcers. Since then, it has become recognized for supporting tissue repair in various clinical settings, including chronic wound healing, dermatological rejuvenation, and hair restoration [5][8].
Molecular Mechanisms of Action
Adenosine A2A Receptor Activation
PDRN primarily promotes regeneration by activating adenosine A2A receptors (A2AR) [5][8][10]. Extracellular enzymes such as ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and ecto-5′-nucleotidase (CD73) degrade PDRN into adenosine, which then interacts with A2ARs on fibroblasts, endothelial cells, and immune cells [3][8]. This interaction increases intracellular cyclic AMP levels, initiating a cascade of signals that promote angiogenesis and reduce inflammation [8][11].
This pathway enables PDRN to increase vascular endothelial growth factor (VEGF) levels, thereby promoting the development of new blood vessels necessary for tissue repair [1][6][7]. It also modulates the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β), helping to shift the local environment from a persistent inflammatory state to one that supports healing [2][11]. Additionally, PDRN promotes osteoblast proliferation and exhibits anti-ischemic effects across several preclinical models [4][6].
Nucleotide Provision via the Salvage Pathway
In addition to activating receptors, PDRN supplies nucleotide precursors, which are taken up by cells via equilibrative nucleoside transporters [3][8]. Within cells, these precursors support DNA synthesis and cellular metabolism, providing fibroblasts and keratinocytes with essential substrates for proliferation and extracellular matrix formation [3][8][11].
This dual mechanism (signaling through A2AR and supplying nucleotides) distinguishes PDRN from conventional growth factors or simple moisturizing agents.
Skin Rejuvenation and Wound Healing
A 2026 narrative review on recovery after aesthetic procedures found that PDRN can be incorporated into post-surgical protocols for treatments like laser resurfacing, chemical peeling, microneedling, and radiofrequency.
The review highlighted that human clinical evidence—including randomized controlled trials, comparative cohort studies, and split-face trials—supports PDRN’s effectiveness in promoting re-epithelialization, reducing erythema, improving scars, and modulating melanogenesis [2][11]. Additionally, PDRN has demonstrated short-term cosmetic results comparable to those of hyaluronic acid filler, with indications of increased biostimulatory stability [2][11].
Injectable PDRN-based products have demonstrated benefits, including improved skin hydration, elasticity, and texture, with minimal risk of irritation or adverse reactions when applied topically [1][2]. Currently, a study is underway assessing a formulation with 0.2 % PDRN, 2 % hyaluronic acid, and 0.1 % niacinamide, administered through needling or microneedling, for treating periocular wrinkles [4][13].
Hair Growth Applications
PDRN has also been studied for its possible role in supporting hair follicle activity. In 2015, a clinical study examined intra-perifollicular injections of autologous platelet-rich plasma (PRP) combined with PDRN in women experiencing female pattern hair loss [2][7].
Compared to the baseline, patients receiving PRP and PDRN injections showed significant improvements in average hair counts (23.2 ± 15.5 %; p < 0.001) and mean hair thickness (16.8 ± 10.8 %; p < 0.001) [2][7][8]. The study found that combination therapy with PRP resulted in greater hair thickness than PDRN alone [2][7][8].
Safety Profile
PDRN shows a strong safety record across various trials and real-world uses, with few adverse events reported [5][8][12]. A 2015 study involving 40 patients found no severe side effects or skin issues in those who received PDRN injections regularly throughout the study period [6][6†L19-L22].
The high temperatures employed in PDRN manufacturing effectively eliminate biological contaminants. The extraction process yields over 95% DNA content, while proteins and peptides are effectively inactivated to reduce immunogenic risks [5][6][8].
Role in EleveXo® Formulations
Both EleveXo™ H (Hair Formula) and EleveXo™ S (Skin Formula) feature PDRN as a regenerative active component, combined with exosomes, growth factors, biomimetic peptides, and low-molecular-weight hyaluronic acid. In these products, PDRN helps to:
- Tissue repair signaling: Activation of the A2AR pathway reduces inflammation and promotes angiogenesis in the dermal and follicular environment.
- Nucleotide provision: Supplying essential building blocks supports the metabolic activity of fibroblasts and keratinocytes, enhancing the overall regenerative capacity of the formulation.
- Wound healing support: Accelerates re-epithelialization and minimizes post-procedure redness, making EleveXo™ especially ideal after microneedling or similar skin resurfacing treatments.
- Hair follicle stimulation: By influencing dermal papilla cell metabolism and enhancing local blood flow, PDRN works in tandem with the exosome-driven signaling in EleveXo-H.
With PDRN integrated with exosomes, growth factors, and peptides, the EleveXo® system offers a multi-pathway approach to tissue renewal, addressing signaling, structural support, and cellular energy requirements simultaneously.
Conclusion
PDRN is a regenerative agent derived from DNA that works through two main mechanisms: activating the adenosine A2A receptor, which triggers anti-inflammatory and pro-angiogenic signals, and supplying nucleotides directly through the salvage pathway to support cellular metabolism and growth.
Clinical evidence confirms its effectiveness in healing chronic wounds, aiding post-procedure skin recovery, and supporting hair restoration, all with a strong safety profile. For clinicians seeking advanced topical regenerative options, PDRN offers a scientifically validated complement to exosome- and peptide-based products.
Disclaimer: This content is provided for educational and informational use only. It is not meant to diagnose, treat, cure, or prevent any medical condition. Always seek advice from a qualified healthcare professional for proper medical guidance.
References
[1] G. Y. Park and B.-C. Jang, “Polydeoxyribonucleotide as a Regenerative Agent in Dermatology and Wound Healing: Mechanisms, Clinical Applications, and Safety,” Keimyung Med. J., vol. 44, no. 1, pp. 9–18, jun. 2025. doi: 10.46308/kmj.2025.00115.
[2] J. Flores Rodríguez, L. Toledo Avelar, K. Yi, et al., “Polydeoxyribonucleotide (PDRN) in Post-procedure Recovery in Aesthetic Medicine: A Narrative Review,” Cureus, vol. 18, no. 5, p. e108886, May 2026. doi: 10.7759/cureus.108886.
[3] M. T. Colangelo, C. Galli, and S. Guizzardi, “The effects of polydeoxyribonucleotide on wound healing and tissue regeneration: a systematic review of the literature,” Regen. Med., vol. 15, no. 8, pp. 1801–1821, Aug. 2020. doi: 10.2217/rme-2020-0061.
[4] “Regenerative Treatment of Periocular Wrinkles With PDRN,” ClinicalTrials.gov, NCT07280637, May 2026. [Online]. Available: https://ichgcp.net/clinical-trials-registry/NCT07280637.
[5] “Polydeoxyribonucleotides as Emerging Therapeutics for Skin Diseases: Clinical Applications, Pharmacological Effects, Molecular Mechanisms, and Potential Modes of Action,” DOAJ, 2025. [Online]. Available: https://doaj.org/article/1abf5c8752304926b74bddbf51a0a9aa.
[6] “Prolenium launches PDRN dermal injection to combat aging,” Personal Care Insights, Feb. 2025. [Online]. Available: https://www.personalcareinsights.com.
[7] M. L. H. Lee, “Therapeutic efficacy of autologous platelet-rich plasma and polydeoxyribonucleotide on female pattern hair loss,” PubMed, 2015. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/25674238.
[8] “Polydeoxyribonucleotide (PDRN) in Dentistry: Narrative Review for Mechanisms and Emerging Clinical Applications,” Tissue Eng. Regen. Med., vol. 23, pp. 209–220, 2026. doi: 10.1007/s13770-025-00776-z.
[9] Y. Kano et al., “Control of hair growth and follicle size by VEGF-mediated angiogenesis,” J. Clin. Invest., vol. 107, no. 4, pp. 409–417, Feb. 2001. doi: 10.1172/JCI11317.
[10] “Polynucleotides in aesthetic medicine: the science, mechanisms and clinical considerations,” J. Aesthetic Nurs., Jan. 2026. [Online]. Available: https://www.magonlinelibrary.com.
[11] J. R. Cortelli, “Treatment of Periocular Wrinkles With the Active Ingredients PDRN, Hyaluronic Acid and Niacinamide, Applied by Needling or Microneedling: Randomized Clinical Trial,” ICH GCP, 2026.
[12] “CGBio’s DCLASSY PDRN receives clinical trial approval from MFDS,” News1 Korea, Apr. 2026. [Online]. Available: https://en.news1.kr.
[13] “Anti-Aging Efficacy of Low-Molecular-Weight Polydeoxyribonucleotide Derived from Paeonia lactiflora,” Read by QxMD, Dec. 2025.
